Payment overview · 2025
General Payments
$83.59
3 reported records · 3 companies
Healthcare provider profile · identity verified
Wayne Plooster, DO
Allopathic & Osteopathic Physicians|Family Medicine · RAPID CITY, SD · NPI 1013101054
Verified facts
What the public records show
CMS Open Payments records show Wayne Plooster, DO received $83.59 in general payments during 2025 across 3 reported records.
Inspire Medical Systems, Inc. accounted for 51.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $42.65 | 51.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.12 | 26.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.82 | 22.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $83.59 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $42.65 | 1 | 2025 |
Source payment records
|
|||||
| LILETTA Normalized: liletta |
Drug | ABBVIE INC. | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Simvastatin | Simvastatin | 597 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 473 | 117 |
| Lisinopril | Lisinopril | 460 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 431 | 101 |
| Omeprazole | Omeprazole | 402 | 106 |
| Losartan Potassium | Losartan Potassium | 397 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 372 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 321 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 308 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 265 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 251 | 56 |
| Metformin Hcl | Metformin Hcl | 248 | 58 |
| Furosemide | Furosemide | 191 | 39 |
| Allopurinol | Allopurinol | 167 | 45 |
| Alendronate Sodium | Alendronate Sodium | 129 | 28 |
| Meloxicam | Meloxicam | 129 | 28 |
| Sertraline Hcl | Sertraline Hcl | 112 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 25 |
| Ezetimibe | Ezetimibe | 104 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 18 |
| Gabapentin | Gabapentin | 103 | 21 |
| Potassium Chloride | Potassium Chloride | 102 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 97 | 19 |
| Trazodone Hcl | Trazodone Hcl | 82 | 21 |
| Eliquis | Apixaban | 78 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 17 |
| Finasteride | Finasteride | 77 | 21 |
| Jardiance | Empagliflozin | 75 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 19 |
| Metformin Hcl Er | Metformin Hcl | 67 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 14 |
| Benazepril Hcl | Benazepril Hcl | 57 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 12 |
| Montelukast Sodium | Montelukast Sodium | 54 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 11 |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Famotidine | Famotidine | 48 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 12 |
| Celecoxib | Celecoxib | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Lansoprazole | Lansoprazole | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 33 |
| Pregabalin | Pregabalin | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | 29 |
| Glyxambi | Empagliflozin/Linagliptin | 36 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 16 |
| Carvedilol | Carvedilol | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Prednisone | Prednisone | 17 | 15 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Nystatin | Nystatin | 15 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Cephalexin | Cephalexin | 12 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $83.59 · 3 records | Inspire Medical Systems, Inc. | ELIQUIS, INSPIRE, LILETTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error